NutriDex

The Supplement Research Compendium
🧠

Piracetam

The original "nootropic" — proven for myoclonus, unproven for memory.

Mixed evidence 🧠Nootropic

✚ Updated · How we grade evidence

Evidence tier
Mixed
Research weight
Citations
8 verified / 8
Classification
Nootropic
❝
What the evidence says. Graded mixed: a 2001 Cochrane review and a 2024 meta-analysis (18 trials, 886 people) found the evidence for dementia/memory inadequate and inconclusive, and the large PASS stroke RCT was negative. The one consistently positive use — high-dose add-on therapy for cortical/progressive-myoclonus epilepsy — is a prescription neurology indication, not the cognitive boost it is sold for online. (Mixed evidence: Conflicting results across studies; benefit uncertain.)

What is Piracetam?

Piracetam is a nootropic used for reduces cortical myoclonus. NutriDex grades the human evidence as Mixed. Piracetam is the prototype 'nootropic,' a pyrrolidone derivative prescribed in parts of Europe and Asia but not approved by the US FDA. Despite decades of use for memory and dementia, the evidence there is weak: the 2001 Cochrane review found benefit only on a vague 'global impression of change' and none on specific cognitive measures, and a 2024 meta-analysis of 18 trials (886 patients) could not confirm any memory effect (SMD 0.75, 95% CI -0.19 to 1.69; very high heterogeneity). The large PASS trial (927 patients) showed no benefit in acute ischemic stroke. The clearest evidence is for high-dose piracetam (up to 24 g/day) as add-on therapy in cortical myoclonus and progressive myoclonus epilepsy, where randomized crossover trials show real, dose-dependent symptom relief. As a 'smart drug' for healthy adults, robust supporting data are essentially absent.

Purported Benefits

✓Reduces cortical myoclonus
✓Adjunct in progressive myoclonus epilepsy
✓Marketed for memory & cognition
✓Studied for dementia

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Reduce cortical myoclonus (add-on)Randomized crossover trials show real, dose-dependent myoclonus relief at high doses; small specialized populations. Moderate ↑ benefit · moderate 2
Improve memory / cognitionCochrane found benefit only on vague global impression; 2024 meta-analysis (18 trials) could not confirm any memory effect. Mixed — no effect · negligible 3
Acute ischemic stroke recovery927-patient PASS RCT showed no benefit; pooled data even hinted at slightly higher early deaths (NS). Moderate — no effect · negligible 2

Dosing & Compounds

Typical Dose
Cognitive trials used 2.4–8 g/day orally; myoclonus trials used up to 24 g/day. Not approved or sold as a dietary supplement in the US.
Active Compounds
Piracetam (2-oxo-1-pyrrolidine acetamide)

Safety & Cautions

Generally well tolerated; common effects are nervousness, agitation, insomnia, weight gain and GI upset. Because it lowers platelet aggregation it is contraindicated in cerebral hemorrhage and should be used cautiously with anticoagulants and antiplatelet drugs (aspirin, warfarin) and before surgery. It is renally cleared, so it is contraindicated in severe renal impairment and needs dose reduction with reduced kidney function; it is not approved as a US dietary supplement, so over-the-counter products are unregulated. Educational only — always check with your doctor or pharmacist before combining Piracetam with any medicine.

Key Studies

Meta-analysis Gouhie 2024 ✓ PubMed
Meta-analysis of 18 trials (886 patients): no clear memory benefit (SMD 0.75, 95% CI -0.19 to 1.69, p=0.12, I-squared 96%); impact undeterminable.
Systematic review Ricci 2012 (Cochrane) ✓ PubMed
Pooled stroke data showed early deaths slightly higher with piracetam (non-significant); no reliable evidence of benefit in acute ischaemic stroke.
Systematic review Flicker 2001 (Cochrane) ✓ PubMed
Across trials, piracetam affected only 'global impression of change'; no benefit on any specific cognitive measure. Evidence inadequate for clinical use.
Meta-analysis Waegemans 2002 ✓ PubMed
Older meta-analysis of 19 placebo trials in dementia/cognitive impairment found a favorable global-impression odds ratio; 3 authors were manufacturer consultants.
RCT De Deyn 1997 (PASS) ✓ PubMed
RCT of 927 acute ischemic stroke patients: 12 g/day piracetam vs placebo showed no difference in neurological recovery at 4 weeks (Orgogozo 57.7 vs 57.6).
RCT Koskiniemi 1998 ✓ Full text
Randomized crossover trial in 20 Unverricht-Lundborg patients: 24 g/day piracetam gave significant, dose-linear myoclonus improvement vs placebo (p=0.005).
RCT Brown 1993 ✓ PubMed
Double-blind add-on trial: piracetam significantly reduced cortical myoclonus and disability scores in patients already on other antimyoclonic drugs.
Review Winblad 2005 (Review) ✓ PubMed
Pharmacology review notes piracetam restores membrane fluidity and neuronal function, but stresses clinical cognitive benefit remains unconfirmed.
8 sources cited · 8 verified Search all studies on PubMed ↗

Common questions about Piracetam

What is Piracetam used for?

Piracetam is most often taken for Reduces cortical myoclonus, Adjunct in progressive myoclonus epilepsy, Marketed for memory & cognition, Studied for dementia. The original "nootropic" — proven for myoclonus, unproven for memory.

Does Piracetam work — what does the evidence say?

Mixed evidence. Conflicting results across studies; benefit uncertain. Piracetam is the prototype 'nootropic,' a pyrrolidone derivative prescribed in parts of Europe and Asia but not approved by the US FDA. Despite decades of use for memory and dementia, the evidence there is weak: the 2001 Cochrane review found benefit only on a vague 'global impression of change' and none on specific cognitive measures, and a 2024 meta-analysis of 18 trials (886 patients) could not confirm any memory effect (SMD 0.75, 95% CI -0.19 to 1.69; very high heterogeneity). The large PASS trial (927 patients) showed no benefit in acute ischemic stroke. The clearest evidence is for high-dose piracetam (up to 24 g/day) as add-on therapy in cortical myoclonus and progressive myoclonus epilepsy, where randomized crossover trials show real, dose-dependent symptom relief. As a 'smart drug' for healthy adults, robust supporting data are essentially absent.

What is the typical dose of Piracetam?

Cognitive trials used 2.4–8 g/day orally; myoclonus trials used up to 24 g/day. Not approved or sold as a dietary supplement in the US.

Is Piracetam safe? Any cautions or side effects?

Generally well tolerated; common effects are nervousness, agitation, insomnia, weight gain and GI upset. Because it lowers platelet aggregation it is contraindicated in cerebral hemorrhage and should be used cautiously with anticoagulants and antiplatelet drugs (aspirin, warfarin) and before surgery. It is renally cleared, so it is contraindicated in severe renal impairment and needs dose reduction with reduced kidney function; it is not approved as a US dietary supplement, so over-the-counter products are unregulated.

How many studies support Piracetam?

NutriDex cites 8 sources for Piracetam, graded "Mixed".

Cite this page
APA

Peh, D. (2026). Piracetam: Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/piracetam

BibTeX
@misc{nutridex_piracetam,
  author       = {Peh, Daryl},
  title        = {Piracetam: Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/piracetam},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances